Head-to-head evidence
efpeglenatide vs PB-119
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
efpeglenatide
Developed by Hanmi Pharmaceutical and partners
NCT03353350 · Phase 3 · completed
The trial was randomized, quadruple-blinded, placebo-controlled, and included 406 participants, providing a strong comparative design. However, the primary endpoint was the surrogate measure of HbA1c change, and although the reported changes favored efpeglenatide, statistical significance for the primary comparison was not reported.
Next expected readout: November 2027 · NCT07379333 (registry estimate)
PB-119
Developed by PegBio
NCT04504396 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · PB-119's landscape